OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review
AUTOR(ES)
Zhang, Rui, Xu, Yongteng, Yang, Shengping, Liang, Hui, Zhang, Yunxin, Liu, Yali
FONTE
Int. braz j urol.
DATA DE PUBLICAÇÃO
2015-04
RESUMO
Purpose To evaluate the efficacy and safety of onabotulinumtoxinA for patients with neurogenic detrusor overactivity (NDO). Materials and Methods We searched the Cochrane Library, PUBMED, EMBASE, Chinese Bio-medicine database, China Journal Full-text Database, VIP database, Wanfang database for randomized controlled trials (from inception to September 2012). Two authors independently selected studies, extracted data and assessed the methodological and evidence quality using the Cochrane Risk of Bias Table and GRADE (Grading of Recommendations, Assessment, Development and Evaluation) respectively. Data analysis was performed by RevMan 5.1 and descriptive analysis was employed if necessary. Results Eight studies were selected (n=1879 participants). OnabotulinumtoxinA was more related to urinary tract infection (UTI) (200U: OR 1.72, CI: 1.18-2.52; 300U: OR 1.88, CI: 1.31-2.69) versus placebo. Also, OnabotulinumtoxinA was superior to placebo in improving maximum cystometric capacity (MCC) (200U: OR 138.80, CI: 112.45-165.15; 300U: OR 152.09, CI: 125.25-178.93) and decreasing maximum detrusor pressure (MDP) (200U: MD -29.61, CI: -36.52--22.69; 300U: MD-28.92, CI: -39.59--18.25). However, there were no statistical differences between 200U and 300U onabotulinumtoxinA in UTI (OR 0.84, CI: 0.58-1.22), MCC (OR-12.72, CI: -43.36-17.92) and MDP (MD 2.21, CI: -6.80-11.22). Conclusions OnabotulinumtoxinA may provide superior clinical and urodynamic benefit for populations with NDO. High-quality studies are required for evaluating the optimal dose, long-term application and when to perform repeated injections.
Documentos Relacionados
- Estudo comparativo entre cloridrato de oxibutinina e onabotulinumtoxina em pacientes portadores de lesão medular com hiperatividade do detrusor : avaliação urodinâmica e qualidade de vida = Comparative study between oxybutynin chloride and onabotulinumtoxinA in spinal cord injured patients with detrusor overactivity urodynamic evaluation and quality of life
- Editorial Comment: Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity
- Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients
- Oxybutynin and tolterodine for treatment of neurogenic detrusor overactivity: a pharmacoeconomic evaluation in the Brazilian context
- Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity